Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Lenalidomide-refractory MM responds to triple therapy
Chari A et al. J Clin Oncol 36, 2018 (suppl, abstr 8002).
Key clinical point: Daratumumab, carfilzomib and dexamethasone (D-Kd) is safe and effective in patients with relapsed multiple myeloma, regardless of prior lenalidomide exposure.
Major finding: 12-month progression-free survival was 71% overall, 62% for lenalidomide-refractory patients, and 87% for lenalidomide-exposed but not refractory patients.
Study details: Subgroup analysis of 85 patients in MMY1001, an open label, phase 1b study.
Disclosures: Ajai Chari, MD, reported disclosures related to Acetylon Pharmaceuticals, Adaptive Biotechnologies, Amgen, Array Biopharma, Bayer, Biotest, Bristol-Myers Squibb, Celgene, Janssen Oncology, Millennium, Novartis, Onyx, Pharmacyclics, Seattle Genetics, and Takeda.
Source: Chari A et al. J Clin Oncol 36, 2018 (suppl, abstr 8002).
Chari A et al. J Clin Oncol 36, 2018 (suppl, abstr 8002).